Bafna Pharmaceuticals Limited (BAFNAPH) — FY26 Annual Report | 19 August 2026

Bafna Pharmaceuticals Limited announced its 31st Annual General Meeting (AGM) to be held on September 11, 2026, via Video Conferencing, and disclosed the Annual Report for FY 2025-26. The company reported robust financial performance with total revenue of ₹1,506.17 million (up 3.26% YoY), operating profit of [amount context mismatch] million (up 43%), and net profit of ₹111 million (up 167%). Key developments include a credit rating upgrade from stable to positive by ICRA, recognition as Emerging Company of the Year in Healthcare, promoter equity streamlining to 74.57% public holding, and asset monetization of its Madhavaram manufacturing unit. The company emphasized strategic expansion into regulated markets, R&D investments, green energy adoption (60% solar power target), and ESG initiatives. No dividend was declared for FY 2025-26. The AGM notice detailed e-voting procedures, quorum requirements, and shareholder participation rules through CDSL's platform.